CTRI/2022/11/047667尚未招募2/3 期
A COMPARATIVE PHARMACO- ANALYTICAL STUDY AND THEIR CLINICAL EVALUATION OF MUKHAKANTIKARA GEL PREPARED BY CHURNA AND EXTRACTS IN VYANGA W S R TO FACIAL MELANOSIS
govt ayurvedic medical college and hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年1月12日最近更新:
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- improvment in MASI scale
研究概览
简要总结
this study is randamized, double blind, parallel group trail comparing the safety and efficacy of mukhakantikara gel prepared by churna and extracts in 40 patients with hyperpigmentation that will be conducted in our institute hospital in india, the primary ontcome of measures will be improvement on MASI scale on 45th day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 15.00 Year(s) 至 50.00 Year(s)(—)
- 性别
- All
入选标准
- •patients with clinical signs of vyanga as per ayurvedic classics will be included.
- •chronicity less than 5 years.
排除标准
- •inflammatory pigmentation hyperpigmentation caused by tumor like malignant melanoma.
- •hyperpigmentation caused by acne vulgaris.
- •hyperpigmentation caused due to systemic diseases.
- •hyperpigmentation since birth.
结局指标
主要结局
improvment in MASI scale
时间窗: follow up on 45th day
次要结局
- improvent in pigmentation(on 45th day)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsHealthy PeopleNCT03651947Qilu Pharmaceutical Co., Ltd.168
Unknown
1 期
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy AdultsHealthy PeopleNCT04213105Qilu Pharmaceutical Co., Ltd.144
已完成
1 期
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®Healthy SubjectsNCT04027803Biocad78
已完成
3 期
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)OsteoarthritisNCT00092352Merck Sharp & Dohme LLC395
已完成
3 期
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)OsteoarthritisNCT00092365Merck Sharp & Dohme LLC413
